Cosmo Pharmaceuticals NV
Company Profile
Business description
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.
Contact
Sir John Rogerson’s Quay
Riverside II
Dublin2
IRLT: +353 18170370
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
339
Stocks News & Analysis
stocks
Is this ASX share a long-term buy?
stocks
Why Guzman and Reece's share reversals have a lot in common
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,477.30 | 20.70 | -0.24% |
CAC 40 | 8,143.92 | 92.85 | 1.15% |
DAX 40 | 22,794.11 | 383.84 | 1.71% |
Dow JONES (US) | 43,422.20 | 39.01 | -0.09% |
FTSE 100 | 8,706.59 | 37.92 | 0.44% |
HKSE | 23,787.93 | 753.91 | 3.27% |
NASDAQ | 19,013.33 | 13.06 | -0.07% |
Nikkei 225 | 38,142.37 | 95.42 | -0.25% |
NZX 50 Index | 12,452.46 | 145.19 | 1.18% |
S&P 500 | 5,946.62 | 8.63 | -0.14% |
S&P/ASX 200 | 8,240.70 | 11.20 | -0.14% |
SSE Composite Index | 3,380.21 | 34.17 | 1.02% |